Table 3.
Primary prevention of death with cardiovascular agents in patients with no atherosclerotic cardiovascular disease
| No needed to treat (95% CI) | Duration (years) | No of
|
Risk reduction (%)
|
||||
|---|---|---|---|---|---|---|---|
| Trials | Patients | Relative | Absolute | ||||
| Antihypertensive drugs*: | |||||||
| Diuretics (decrease 10.0) | 43 (26 to 243)† | 5.6 | 4 | 3 141 | 18 | 2.2 | |
| Diuretics (decrease 5.7) | 213 (136 to 552)† | 5.4 | 11 | 48 013 | 8 | 0.4 | |
| β blockers (decrease 6) | 332 (18 to −18) | 5.2 | 3 | 22 729 | 6 | 0.3 | |
| Antidyslipidaemic drugs: | |||||||
| Pravastatin | 126 (71 to 24035)† | 4.3 | 2 | 7 657 | 22 | 0.7 | |
| Diet | 85 (42 to −88) | 9 | 1 | 1 232 | 31 | 1.1 | |
| Resin | 203 (78 to −192) | 5.4 | 2 | 6 084 | 13 | 0.4 | |
| Gemofibrozil | −799 (161 to −79) | 5 | 1 | 4 081 | −5 | −0.1 | |
| Clofibrate | −156 (−5398 to −70)† | 5.3 | 1 | 10 627 | −26 | −0.6 | |
| Aspirin | 340 (149 to −765) | 5.2 | 2 | 27 212 | 8 | 0.2 | |
*
In the absence of known atherosclerotic cardiovascular disease. Bracketed data refers to decrease in diastolic blood pressure.
†
Statistically significant, values are not normalised to trial duration (negative number needed to treat indicates that screening increased mortality).